Heron Therapeuti (HRTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $59.08M
Last updated: Nov 17, 2026 at 11:06 AM ET
Heron Therapeuti (HRTX) Stock Forecast
Analysts expect Heron Therapeuti (HRTX) to earn -$0.14 per share in the fiscal year ending Dec 31, 2026, on revenue of $141.60M. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.12.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 0.8%.
- Fiscal year ending Dec 31, 2026
- -$0.14
- EPS consensus, revenue $141.60M
- Fiscal year ending Dec 31, 2027
- -$0.12
- EPS consensus, revenue $140.40M
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.14 | -$0.15 to -$0.12 | 2 | $141.60M | $139.10M to $144.10M | 2 |
| Dec 31, 2027 | -$0.12 | -$0.14 to -$0.10 | 2 | $140.40M | $140.40M to $140.40M | 1 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.03 | -$0.04 to -$0.02 | 4 | $34.68M | $30.87M to $38.33M | 4 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 0 upward and 2 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.13.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.14 | -$0.13 | -$0.13 | -$0.13 | -$0.13 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.12 | -$0.11 | -$0.11 | -$0.11 | -$0.11 | N/A |
Frequently Asked Questions About HRTX
What is the HRTX stock forecast?
Consensus analyst estimates put Heron Therapeuti's EPS at -$0.14 for the fiscal year ending Dec 31, 2026, on revenue of $141.60M.
What EPS do analysts expect from HRTX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.14, with estimates from -$0.15 to -$0.12 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.12, with estimates from -$0.14 to -$0.10 from 2 analysts.
What revenue do analysts expect from Heron Therapeuti next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $141.60M, with estimates from $139.10M to $144.10M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $140.40M, with estimates from $140.40M to $140.40M.
How many analysts cover HRTX?
2 analysts estimate EPS for Heron Therapeuti for the fiscal year ending Dec 31, 2026.
HRTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors